GQG Partners LLC grew its stake in Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) by 359.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 2,008,759 shares of the company's stock after acquiring an additional 1,571,808 shares during the period. GQG Partners LLC owned about 0.24% of Dr. Reddy's Laboratories worth $31,718,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Natixis Advisors LLC increased its holdings in Dr. Reddy's Laboratories by 7.2% in the 3rd quarter. Natixis Advisors LLC now owns 10,937 shares of the company's stock valued at $869,000 after purchasing an additional 735 shares during the last quarter. EverSource Wealth Advisors LLC increased its stake in Dr. Reddy's Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company's stock worth $29,000 after purchasing an additional 1,507 shares during the period. POM Investment Strategies LLC lifted its position in shares of Dr. Reddy's Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company's stock worth $36,000 after purchasing an additional 1,820 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Dr. Reddy's Laboratories by 461.0% in the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company's stock valued at $40,000 after purchasing an additional 2,093 shares during the period. Finally, Independence Bank of Kentucky boosted its stake in shares of Dr. Reddy's Laboratories by 400.0% in the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company's stock valued at $44,000 after purchasing an additional 2,220 shares during the period. 3.85% of the stock is owned by hedge funds and other institutional investors.
Dr. Reddy's Laboratories Stock Down 0.6 %
NYSE:RDY traded down $0.08 during mid-day trading on Friday, hitting $13.20. The stock had a trading volume of 2,048,621 shares, compared to its average volume of 1,317,508. Dr. Reddy's Laboratories Limited has a twelve month low of $12.50 and a twelve month high of $16.89. The stock has a 50-day simple moving average of $13.48 and a two-hundred day simple moving average of $14.60. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $11.01 billion, a PE ratio of 21.01 and a beta of 0.48.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last announced its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, equities research analysts anticipate that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on RDY shares. StockNews.com lowered shares of Dr. Reddy's Laboratories from a "buy" rating to a "hold" rating in a report on Friday, December 6th. Nomura cut Dr. Reddy's Laboratories from a "buy" rating to a "neutral" rating in a research note on Thursday, December 19th.
Read Our Latest Stock Analysis on Dr. Reddy's Laboratories
About Dr. Reddy's Laboratories
(
Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Read More
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
